Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 10, 2017 Filed Nov 13, 2017 21:36 UTC |
Schor ChenDirector
|
GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-058397 · tv479017_4.xml · nonDerivative · entry 1 Schor Chen · CIK 0001340875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,558 F1 · shares: Shares acquired are shares of restricted stock awarded on November 10, 2017 pursuant to the Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on December 10, 2017 until fully vested on the first anniversary of the date of grant, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date. Read SEC document |
| August 31, 2017 Filed Aug 31, 2017 20:08 UTC |
ARBEL IRITDirector
|
PurchaseCommon Stock | 2,500 | $4.26 | $10,650.00 |
DisclosureSEC source: 0001144204-17-046175 · v474446_4.xml · nonDerivative · entry 1 ARBEL IRIT · CIK 0001245607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,833 Read SEC document |
| August 23, 2017 Filed Aug 23, 2017 18:22 UTC |
Yablonka UriDirector · EVP & Chief Business Officer
|
PurchaseCommon Stock | 2,000 | $3.98 | $7,960.00 |
DisclosureSEC source: 0001144204-17-044724 · v473922_4.xml · nonDerivative · entry 1 Yablonka Uri · CIK 0001608814 · Director · EVP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,543 Read SEC document |
| July 26, 2017 Filed Jul 26, 2017 21:29 UTC |
Lebovits ChaimSee Remarks
|
GrantStock Option (right to buy) · Derivative | 41,580 | $0.00 Strike: $4.81 | $0.00 |
DisclosureSEC source: 0001144204-17-038410 · v471333_4.xml · derivative · entry 2 Lebovits Chaim · CIK 0001406302 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,580 Underlying: Common Stock · 41,580 shares Expires 2019-07-26 F3 · derivative.exercise_date: Option is fully vested exercisable as of the date of grant and shall remain exercisable until the 2nd anniversary of the date of grant. Read SEC document |
| July 26, 2017 Filed Jul 26, 2017 21:29 UTC |
Lebovits ChaimSee Remarks
|
GrantCommon Stock | 31,185 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-038410 · v471333_4.xml · nonDerivative · entry 1 Lebovits Chaim · CIK 0001406302 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,103,785 F1 · shares: Shares acquired are shares of restricted stock awarded on July 26, 2017 under the Issuer's 2014 Global Share Option Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of the date of grant, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date. F2 · balance_after: Includes (i) 1,933,794 shares of Common Stock owned by ACCBT Corp. and (ii) 138,806 shares of Common Stock owned by ACC International Holdings Ltd. Reporting Person may be deemed the beneficial owner of these shares. Read SEC document |
| July 13, 2017 Filed Jul 17, 2017 21:01 UTC |
ARBEL IRITDirector
|
GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001144204-17-037014 · v470752_4.xml · derivative · entry 1 ARBEL IRIT · CIK 0001245607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2028-07-13 F1 · derivative.exercise_date: Option is fully vested and exercisable on the date of grant. Read SEC document |
| July 13, 2017 Filed Jul 17, 2017 21:00 UTC |
Yablonka UriDirector · EVP & Chief Business Officer
|
GrantCommon Stock | 5,543 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-037012 · v470768_4.xml · nonDerivative · entry 1 Yablonka Uri · CIK 0001608814 · Director · EVP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,543 Read SEC document |
| March 06, 2017 Filed Mar 6, 2017 21:05 UTC |
Kern Ralph Dr.COO and Chief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 47,847 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001144204-17-012940 · v461202_4.xml · derivative · entry 2 Kern Ralph Dr. · CIK 0001699684 · COO and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,847 Underlying: Common Stock · 47,847 shares Expires 2019-03-06 F2 · derivative.exercise_date: Option is fully vested and exercisable as of the date of grant and shall remain exercisable until the 2nd anniversary of the date of grant. Read SEC document |
| March 06, 2017 Filed Mar 6, 2017 21:05 UTC |
Kern Ralph Dr.COO and Chief Medical Officer
|
GrantCommon Stock | 35,885 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-012940 · v461202_4.xml · nonDerivative · entry 1 Kern Ralph Dr. · CIK 0001699684 · COO and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,885 F1 · shares: Shares acquired are shares of restricted stock awarded on March 6, 2017 under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of the date of grant, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date. Read SEC document |
| February 26, 2017 Filed Feb 28, 2017 22:18 UTC |
ARBEL IRITDirector
|
GrantStock Option (right to buy) · Derivative | 6,667 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001144204-17-011827 · v460623_4.xml · derivative · entry 2 ARBEL IRIT · CIK 0001245607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 Underlying: Common Stock · 6,667 shares Expires 2027-02-26 F2 · derivative.exercise_date: Option is fully vested and exercisable on the date of grant. Read SEC document |
| February 26, 2017 Filed Mar 3, 2017 22:33 UTC |
Araya ArturoDirector
|
GrantCommon Stock | 3,012 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-012785 · v460632_4.xml · nonDerivative · entry 1 Araya Arturo · CIK 0001699800 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,012 F1 · shares: Shares acquired are shares of restricted stock awarded on February 26, 2017 pursuant to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on March 26, 2017 until fully vested on the first anniversary of the date of grant, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.